Trial Profile

A study assessing EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 17 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EO 1022 (Primary)
Indications Breast cancer; Solid tumours
Focus Adverse reactions

Most Recent Events

17 Dec 2024 New trial record
12 Dec 2024 According to Elevation Oncology media release, the company expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com